Skip to content
Home/Companies/Biotech/Eliem Therapeutics

Eliem Therapeutics

Biotech·US·Exited 2021·Held under 1yr
Entry
2021
Hold
<1yr
Exit
2021

Who owns Eliem Therapeutics?

Eliem Therapeutics was owned by LifeArc through LifeArc Ventures (1992 vintage) from 2021 to 2021, exited via IPO.

Hand-verified · updated 2026-08-03

LifeArc
Investor
LifeArc
LifeArc Ventures · 1992 · Life Sciences VC

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2021

More from LifeArc Ventures

Other portfolio companies in the same fund.

Exciva
Active
BiotechGermany· 2026
GlycoEra
Active
BiotechSwitzerland· 2025
Hillstar Bio
Active
BiotechUS· 2025
Tribune Therapeutics
Active
BiotechSweden· 2025
Fluid Biomed
Fluid Biomed
Active
MedTechCanada· 2024
Affect Therapeutics
Affect Therapeutics
Active
HealthTechUS· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Eliem Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Eliem Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Eliem Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue